… vaccine against SARS-CoV or MERS-CoV have been tried with limited success. Since
SARS-CoV… the most preferred targets for making vaccines or therapeutics against SARS-CoV-2. In …

… severity and ability to evade vaccine-induced and natural immunity. Here … SARS-CoV-2
structural and non-structural proteins and their impact on diagnostics, therapeutics and vaccines. …

… the severity of SARS virus infections and to prevent or treat SARS virus–associated disease
[… weeks after immunization with the MNA delivered SARS-CoV-2, S1 subunit vaccine showed …

… will only be contained when an efficient therapy or vaccine will become available. This …
SARS-CoV-2, the pathophysiology of the infection, the treatments currently tested, and vaccines …

… Here, we provide insight into the leading vaccines and their advantages and challenges…
SARS-CoV-2 spike protein and other issues that need to be addressed to overcome coronavirus …

… the therapeutic drugs that directly target SARS-CoV-2 will be most effective. Besides, vaccines
… advances in deciphering SARS-Cov-2 will lead to additional potential therapeutic targets. …

… against the SARS coronavirus family.[ 95 ] The second group of prophylactic agents may
constitute of factors that enhances the anti-viral host immune response such as Imiquimod (…

… The leading mRNA SARS CoV-2 vaccine candidate is being developed as a collaboration
between the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna. Their …

… , no specific vaccines or ideal drugs for SARS-CoV-2 have … drugs and vaccines to respond
to outbreaks of SARS-CoV-2 (… be good news regarding SARS-CoV-2 vaccines, as a result …

… therapeutic strategies against COVID-19, namely drugs targeting the SARS-CoV-2 life cycle
and SARS-CoV-2-… The development of above two strategies is implemented by repurposing …